Κωνσταντίνος Τούτουζας

Transcript

1 TAVI Διαδερµικά τοποθετούµενες συσκευές στην αορτική βαλβίδα. Είµαστε έτοιµοι για την χρήση τους σε µετρίου ή χαµηλού κινδύνου ασθενείς στην Ελλάδα Κωνσταντίνος Τούτουζας Αν. Καθηγητής Καρδιολογίας Α Πανεπιστηµιακή Καρδιολογική Κλινική Ιπποκράτειο Νοσοκοµείο

2 Patient Selection TCT 2014

3 2014 ACC/AHA Guidelines Valvular Heart Disease Nishimura et al., Circulation, 2014

4 Trends in TAVI - Rising number of procedures - Age is decreasing N= AVR= TAVI= Reinohl et al., NEJM 2015

5 Υψηλού κινδύνου TAVI

6 PARTNER A Trial: 5 Years Median Survival Time M. Mack, ACC 2015

7 PARTNER B: 5 Years Median Survival Time Samir Kapadia, TCT 2014

8

9

10

11

12

13

14 Υψηλού κινδύνου Μετρίου κινδύνου TAVI

15 SAPIEN 3 TAVI superior to surgery V. Thourani et al, Lancet, 2016

16 NOTION Trial Randomization to CoreValve or surgery Average STS score was about 3.0 and more than 80% had a score of less than 4

17 NOTION Trial 2-year outcomes Equivalence between the 2 methods Søndergaard L et al, Circ Cardiovasc Interv, 2016

18 SURTAVI Trial Trial Design Up to 2500 patients at up to 75 global sites will be included in the trial. All patients will complete a minimum of 24 months of in clinic follow-up. Clinical endpoints will be reported and adjudicated according to Valve Academic Research Consortium (VARC) standard endpoint definitions.

19 SURTAVI Trial Propensity Score Matching Among Intermediate-Risk Surgical Patients Cumulative all-cause mortality at 30 days and 1 year was similar STS trend N. Piazza et al, JACC Interv, 2013

20 PARTNER 2 TAVI: More MVC M. Leon et al, NEJM, 2016

21 ACC 2016

22 ACC 2016

23 ACC 2016

24 ACC 2016

25 ACC 2016

26 TAVI Υψηλού κινδύνου Μετρίου κινδύνου Προβληµατισµοί: Βηµατοδότες, PVL, µακροχρόνια αποτελέσµατα Ειδικοί πληθυσµοί

27 Remaining Challenges

28 The prevalence of implanted cardiovascular electronic devices in transcatheter aortic valve implantation patients. ICED, implanted cardiovascular electronic devices; CV, CoreValve; ES, Edward Sapien valve; PPM, permanent pacemaker. Mohammad Abdelghani et al. EHJ 04/2016

29 Cut-points of paravalvular leakage severity that are linked to worse prognosis Technique Parameter, cutpoint Risk Mohammad Abdelghani et al. EHJ 04/2016

30 Impact of AR on Mortality CoreValve Pivotal Trial Popma et al. JACC 2014

31 Effect of Acuteness of AR on Mortality After TAVI: Multicenter Study (1735 Patients) Jerez-Valero et al. JACC Intv

32 Representation of the location of infective endocarditis (IE) in patients with previous transcatheter aortic valves Ignacio J. Amat-Santos et al. Circulation 3/2015

33 Survival after aortic valve replacement with mechanical valves vs. bioprostheses.

34 Survival after aortic valve replacement with mechanical valves vs. bioprostheses

35 Risk of stroke, reoperation, major bleeding, and cardiovascular death, mechanical valves vs. bioprostheses

36 TAVI Υψηλού κινδύνου Μετρίου κινδύνου Προβληµατισµοί: Βηµατοδότες, PVL, µακροχρόνια αποτελέσµατα Ειδικοί πληθυσµοί

37 Οριζόντια Αορτή Α Πανεπιστηµιακή Καρδιολογική Κλινική

38 Θρόµβος

39 Θρόµβος

40 Real Life 2

41 Real Life 2

42 Real Life 2

43 Real Life 2

44 RealLife 2

45 Real Life 2

46 Μεταλλική µιτροειδούς

47 Μεταλλική µιτροειδούς

48 Predilatation The DIRECT Trial The predilation in transcatheter aortic valve implantation Trial (NCT ) Patient evaluation by Heart Team 3 International TAVI Centers Hippokration Hospital: Core Lab TAVI 1:1 Randomization N= 170 randomized patients BAV No-BAV Primary endpoint: Device success based on VARC-2 Secondary endpoint: In-hospital death, stroke, PPM, mortality

49 ipad App PCR Valve Atlas (2014) Special Contributors G. Latsios A. Synetos K. Toutouzas

50 Conclusions Aortic stenosis has become a fully treatable disease entity. TAVI has shown great long-term results. TAVI results > 10 years are eagerly awaited. Novel TAVI devices are constantly being developed. Newer indications for TAVI are aortic insufficiency and mediumrisk patients. The HEART TEAM should be involved when dealing with patients.

51 Μελλοντικές Προοπτικές - Size (14 Fr) - Risk scores - Concomitant valvular disorders - Alternative routes - Balloon predilatation - Anti-coagulation - Pacemaker - VIV -Need for back-up

52 TAVI Increase in available valves Size availability K. Toutouzas, K. Stathogiannis, G. Latsios, A. Synetos, C. Stefanadis, Rec Pat Cardiovasc Dr Disc

53 Προγνωστικά Μοντέλα στην TAVI Χρησµοί της Πυθίας ή Επιστηµονικά δεδοµένα; Risk scores STS score and log EuroSCORE have low c-indexes between Although the 3 scores were not predictive for 30 day mortality the updated EuroSCORE II had better accuracy with area under curve of The STS score had the worse predictive value in short term mortality and there was no difference in STS score between survivals and non-survivals 410±22 days. Toutouzas K, Stefanadis C., Cardiology, 2013

54 Trans-carotid TAVI Alternative routes Guyton, CCI 2012 Thourani, ATS 2013

55 Trans-caval TAVI Crossing Alternative routes Sheath insertion Greenbaum, PCR 2014

56 Direct TAVI with CoreValve 1 Year Outcomes Predilatation K. Toutouzas et al., IJC 2015 / ACC 2015

57 TAVI for failed surgical bioprostheses 1-Year outcomes from PARTNER II V-I-V Registry TCT 2015

58 German TAVI Registry Need for on-site cardiac surgery? Similar mortality rates for both groups CS hospitals: 1254 non-cs hospitals: 178 Eggebrecht et al., Eurointervention, 2015

59 Need for extracorporeal circulation? K. Toutouzas et al., CCI, 2015

60 Νεότερα δεδοµένα 2016 Μακροχρόνια αποτελέσµατα Νεότερες βαλβίδες Μελλοντικές προοπτικές Πειραµατικά µοντέλα

61 Inflammation and thermal heterogeneity in aortic stenosis Inflammatory CD3 infiltrates in AVS Association of inflammatory and neovascularization factors with temperature differences Toutouzas K, Drakopoulou M, Synetos A, Tsiamis E, Agrogiannis G, Kavantzas N, Patsouris E, Iliopoulos D, Theodoropoulos S, Yacoub M, Stefanadis C JACC

62 Topical infusion of bisphosphonates Effect on arterial wall calcification Placebo Zolendronate Αντιπροσωπευτικές τοµές µε χρώση Von Kossa από το ίδιο ζώο. Η περιεκτικότητα σε ασβέστιο είναι πολύ µικρότερη στην αρτηρία όπου έγινε τοπική έγχυση διφωσφονικού Toutouzas K, Synetos A, Benetos G, Drakopoulou M, Trantalis G., Kotronias R., Agrogiannis G., Tsiamis E., Deutereos S, Davlouros P, Patsouris E, Stefanadis C, Int. J Cardiol

63 Topical infusion of bisphosphonates Effect on arterial wall calcification Valve Leaflet Zolendronate Valve Leaflet

64 Experimental animal model of aortic stenosis Use of PET/CT on detecting calcification Aortic valve stenosis Control 1 st Department of Cardiology, Athens Medical School

65 Conclusions Aortic stenosis has become a fully treatable disease entity. TAVI has shown great long-term results. TAVI results > 10 years are eagerly awaited. Novel TAVI devices are constantly being developed. Newer indications for TAVI are aortic insufficiency and mediumrisk patients. The HEART TEAM should be involved when dealing with patients.

66 ACC 2016

67 ACC 2016

68 ACC 2016

69 ACC 2016

70 ACC 2016

71 ACC 2016

72 ACC 2016

73 ACC 2016

74 ACC 2016

75 ACC 2016

76 ACC 2016

77 ACC 2016

78 ACC 2016

79 ACC 2016

80 ACC 2016

81 ACC 2016

82 Θρόµβος

83 Θρόµβος

84 Θρόµβος

85 Θρόµβος

86 Θρόµβος

87 Θρόµβος

88 Predilatation The DIRECT Trial The predilation in transcatheter aortic valve implantation Trial (NCT ) Patient evaluation by Heart Team 3 International TAVI Centers Hippokration Hospital: Core Lab TAVI 1:1 Randomization N= 170 BAV No-BAV Primary endpoint: Device success based on VARC-2 Secondary endpoint: In-hospital death, stroke, PPM, mortality

89 Real Life 1

90 Real Life 1

91 Real Life 1

92 Real Life 1

93 Real Life 1

94 Real Life 1

95 Real Life 1

96 Real Life 1

97 Real Life 1

98 Real Life 2

99 RealLife 2

100 Real Life 3

101 Real Life 3

102 Real Life 3

103 Real Life 4

104 Real Life 4

105 Real Life 4

106 Real Life 4

107 Real Life 4

108 Real LIfe 4

109 12-month follow-up in patients diagnosed with infective endocarditis (IE) after transcatheter aortic valve implantation time 0 represents the time of IE diagnosis Ignacio J. Amat-Santos et al. Circulation 3/2015

110